JP2012510993A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012510993A5 JP2012510993A5 JP2011539520A JP2011539520A JP2012510993A5 JP 2012510993 A5 JP2012510993 A5 JP 2012510993A5 JP 2011539520 A JP2011539520 A JP 2011539520A JP 2011539520 A JP2011539520 A JP 2011539520A JP 2012510993 A5 JP2012510993 A5 JP 2012510993A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- optionally
- free
- salt form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims 46
- 125000003118 aryl group Chemical group 0.000 claims 34
- -1 aryl luma Chemical compound 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 150000003839 salts Chemical group 0.000 claims 14
- 229910052799 carbon Inorganic materials 0.000 claims 13
- 125000005843 halogen group Chemical group 0.000 claims 13
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000005549 heteroarylene group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 2
- 125000000732 arylene group Chemical group 0.000 claims 2
- 230000006315 carbonylation Effects 0.000 claims 2
- 238000005810 carbonylation reaction Methods 0.000 claims 2
- 125000005241 heteroarylamino group Chemical group 0.000 claims 2
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 241000238366 Cephalopoda Species 0.000 claims 1
- 241000023320 Luma <angiosperm> Species 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 0 C*(C1)(C2*)*1(C)C(*)(*)N=C(N(*)C(C1=C(N)I*)=O)N2C1=NC Chemical compound C*(C1)(C2*)*1(C)C(*)(*)N=C(N(*)C(C1=C(N)I*)=O)N2C1=NC 0.000 description 6
- KKJWYLGEEIGXKY-MSLYCLFWSA-N CN(C1=N[C@H](CCC2)[C@H]2N1c1n[n](Cc(cc2)ccc2-c2cccc(F)n2)c(S(c2ccccc2)=O)c11)C1=O Chemical compound CN(C1=N[C@H](CCC2)[C@H]2N1c1n[n](Cc(cc2)ccc2-c2cccc(F)n2)c(S(c2ccccc2)=O)c11)C1=O KKJWYLGEEIGXKY-MSLYCLFWSA-N 0.000 description 2
- BWWMTDSQDBVSTD-MSOLQXFVSA-N CN(C1=N[C@H](CCC2)[C@H]2N1c1n[n](Cc(cc2)ccc2-c2cccc(F)n2)c(SC)c11)C1=O Chemical compound CN(C1=N[C@H](CCC2)[C@H]2N1c1n[n](Cc(cc2)ccc2-c2cccc(F)n2)c(SC)c11)C1=O BWWMTDSQDBVSTD-MSOLQXFVSA-N 0.000 description 2
- UUDXWZNIEMXNPC-PKTZIBPZSA-N CN(C1=N[C@H](CCC2)[C@H]2N1c1n[n](Cc(cc2)ccc2-c2cccc(F)n2)c(Sc2ccccc2)c11)C1=O Chemical compound CN(C1=N[C@H](CCC2)[C@H]2N1c1n[n](Cc(cc2)ccc2-c2cccc(F)n2)c(Sc2ccccc2)c11)C1=O UUDXWZNIEMXNPC-PKTZIBPZSA-N 0.000 description 2
- JCKMKEGCPWQQNW-RTWAWAEBSA-N CN(C1=N[C@H](CCC2)[C@H]2N1c1n[n](Cc(cc2)ccc2-c2cccc(F)n2)c(Sc2ncccc2)c11)C1=O Chemical compound CN(C1=N[C@H](CCC2)[C@H]2N1c1n[n](Cc(cc2)ccc2-c2cccc(F)n2)c(Sc2ncccc2)c11)C1=O JCKMKEGCPWQQNW-RTWAWAEBSA-N 0.000 description 2
- YIXXXUZODMRZPT-SJORKVTESA-N CSc([n](Cc(cc1)ccc1-c1cccc(F)n1)nc1N2C(N3)=N[C@H]4[C@@H]2CCC4)c1C3=O Chemical compound CSc([n](Cc(cc1)ccc1-c1cccc(F)n1)nc1N2C(N3)=N[C@H]4[C@@H]2CCC4)c1C3=O YIXXXUZODMRZPT-SJORKVTESA-N 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical class [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical class C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- LXUVCOJHWZLYEI-IVBQKCMFSA-N CC(C)(C1)CN=C(N(C)C(/C2=C(/NCc(cc3)ccc3Cl)\S(c(cc3)ccc3F)(=O)=O)=O)N1C2=N Chemical compound CC(C)(C1)CN=C(N(C)C(/C2=C(/NCc(cc3)ccc3Cl)\S(c(cc3)ccc3F)(=O)=O)=O)N1C2=N LXUVCOJHWZLYEI-IVBQKCMFSA-N 0.000 description 1
- BDXPWLPFVQDCSR-PWBAXPPHSA-O CC(C)(CN1C(/C2=C(\NCc3ccc(C(F)(F)F)cc3)/S(c3ccccc3)(=O)=O)=[NH2+])N=C1N(C)C2=O Chemical compound CC(C)(CN1C(/C2=C(\NCc3ccc(C(F)(F)F)cc3)/S(c3ccccc3)(=O)=O)=[NH2+])N=C1N(C)C2=O BDXPWLPFVQDCSR-PWBAXPPHSA-O 0.000 description 1
- XEDORQPIOURYOG-DLQVPRDJSA-N CC(C)[C@H](CN1C(/C2=C(\NCc3ccc(C(F)(F)F)cc3)/Sc(cc3)ccc3O)=N)N=C1N(C)C2=O Chemical compound CC(C)[C@H](CN1C(/C2=C(\NCc3ccc(C(F)(F)F)cc3)/Sc(cc3)ccc3O)=N)N=C1N(C)C2=O XEDORQPIOURYOG-DLQVPRDJSA-N 0.000 description 1
- VBNQYFMGKYUBLQ-FHLZENDYSA-N CN(C1=NC(CCC2)C2N1C(/C1=C(\NCc(cc2)ccc2-c2ccccc2)/S(c(cc2)ccc2F)(=O)=O)=N)C1=O Chemical compound CN(C1=NC(CCC2)C2N1C(/C1=C(\NCc(cc2)ccc2-c2ccccc2)/S(c(cc2)ccc2F)(=O)=O)=N)C1=O VBNQYFMGKYUBLQ-FHLZENDYSA-N 0.000 description 1
- MDJQDKIBJMAJOK-GGFKVMBASA-O CN(C1=NC(CCCC2)C2N1C(/C1=C(\NCc2ccc(C(F)(F)F)cc2)/Sc2ccccc2)=[NH2+])C1=O Chemical compound CN(C1=NC(CCCC2)C2N1C(/C1=C(\NCc2ccc(C(F)(F)F)cc2)/Sc2ccccc2)=[NH2+])C1=O MDJQDKIBJMAJOK-GGFKVMBASA-O 0.000 description 1
- LFAIQBITTKITAQ-IOUYNQRBSA-N CN(C1=N[C@@H](CCC2)[C@@H]2N1C(/C1=C(\NCc2ccc(C(F)(F)F)cc2)/Sc2ccccc2)=N)C1=O Chemical compound CN(C1=N[C@@H](CCC2)[C@@H]2N1C(/C1=C(\NCc2ccc(C(F)(F)F)cc2)/Sc2ccccc2)=N)C1=O LFAIQBITTKITAQ-IOUYNQRBSA-N 0.000 description 1
- MDWVHNDENOEJGZ-BWFRZDNYSA-N CN(C1=N[C@@H](CCCC2)[C@@H]2N1C(/C1=C(\NCc(cc2)ccc2-c2ncccc2)/S(c2ccccc2)=O)=N)C1=O Chemical compound CN(C1=N[C@@H](CCCC2)[C@@H]2N1C(/C1=C(\NCc(cc2)ccc2-c2ncccc2)/S(c2ccccc2)=O)=N)C1=O MDWVHNDENOEJGZ-BWFRZDNYSA-N 0.000 description 1
- KHDUOCAUQFDYKR-SZNYOIBYSA-N CN(C1=N[C@H](CCC2)[C@H]2N1C(/C1=C(\NCc(cc2)ccc2-c2ncccc2)/S(c2ccccc2)=O)=N)C1=O Chemical compound CN(C1=N[C@H](CCC2)[C@H]2N1C(/C1=C(\NCc(cc2)ccc2-c2ncccc2)/S(c2ccccc2)=O)=N)C1=O KHDUOCAUQFDYKR-SZNYOIBYSA-N 0.000 description 1
- FSAAJDSEQYKNDQ-HZKCDRNSSA-O CN(C1=N[C@H](CCC2)[C@H]2N1C(/C1=C(\NCc(cc2)ccc2-c2ncccc2)/Sc2ccccc2)=[NH2+])C1=O Chemical compound CN(C1=N[C@H](CCC2)[C@H]2N1C(/C1=C(\NCc(cc2)ccc2-c2ncccc2)/Sc2ccccc2)=[NH2+])C1=O FSAAJDSEQYKNDQ-HZKCDRNSSA-O 0.000 description 1
- NMDGAYFDPHVHKH-MSOLQXFVSA-N CN(C1=N[C@H](CCC2)[C@H]2N1c1n[n](Cc(cc2)ccc2-c2cccc(F)n2)c(S(C)(=O)=O)c11)C1=O Chemical compound CN(C1=N[C@H](CCC2)[C@H]2N1c1n[n](Cc(cc2)ccc2-c2cccc(F)n2)c(S(C)(=O)=O)c11)C1=O NMDGAYFDPHVHKH-MSOLQXFVSA-N 0.000 description 1
- PAVHQSKDUSIPQO-RQRDFJDXSA-N CN(C1=N[C@H](CCC2)[C@H]2N1c1n[n](Cc(cc2)ccc2-c2cccc(F)n2)c([S@@](C)=O)c11)C1=O Chemical compound CN(C1=N[C@H](CCC2)[C@H]2N1c1n[n](Cc(cc2)ccc2-c2cccc(F)n2)c([S@@](C)=O)c11)C1=O PAVHQSKDUSIPQO-RQRDFJDXSA-N 0.000 description 1
- PAVHQSKDUSIPQO-MZDMPTQBSA-N CN(C1=N[C@H](CCC2)[C@H]2N1c1n[n](Cc(cc2)ccc2-c2cccc(F)n2)c([S@](C)=O)c11)C1=O Chemical compound CN(C1=N[C@H](CCC2)[C@H]2N1c1n[n](Cc(cc2)ccc2-c2cccc(F)n2)c([S@](C)=O)c11)C1=O PAVHQSKDUSIPQO-MZDMPTQBSA-N 0.000 description 1
- JMKUWPNQTMLAOO-LFJDEJNOSA-N CN(C1=N[C@H](CCCC2)[C@H]2N1C(/C1=C(\NCC2CCCCC2)/S(c(cc2)ccc2F)(=O)=O)=N)C1=O Chemical compound CN(C1=N[C@H](CCCC2)[C@H]2N1C(/C1=C(\NCC2CCCCC2)/S(c(cc2)ccc2F)(=O)=O)=N)C1=O JMKUWPNQTMLAOO-LFJDEJNOSA-N 0.000 description 1
- XDTSOBSHTMMSBI-HHPIGJHJSA-N CN(C1=N[C@H](CO)CN1C(/C1=C(\NCc2ccc(C(F)(F)F)cc2)/Sc2ccccc2)=N)C1=O Chemical compound CN(C1=N[C@H](CO)CN1C(/C1=C(\NCc2ccc(C(F)(F)F)cc2)/Sc2ccccc2)=N)C1=O XDTSOBSHTMMSBI-HHPIGJHJSA-N 0.000 description 1
- CNQSPIGJWIZWBY-LUWBCPACSA-N C[C@H](CN1C(/C2=C(\NCc(cc3)ccc3-c3ccccc3)/S(c3ccccc3)(=O)=O)=N)N=C1N(C)C2=O Chemical compound C[C@H](CN1C(/C2=C(\NCc(cc3)ccc3-c3ccccc3)/S(c3ccccc3)(=O)=O)=N)N=C1N(C)C2=O CNQSPIGJWIZWBY-LUWBCPACSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12044208P | 2008-12-06 | 2008-12-06 | |
| US61/120,442 | 2008-12-06 | ||
| PCT/US2009/006439 WO2010065149A1 (en) | 2008-12-06 | 2009-12-07 | Organic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012510993A JP2012510993A (ja) | 2012-05-17 |
| JP2012510993A5 true JP2012510993A5 (cg-RX-API-DMAC10.html) | 2014-07-31 |
| JP5778582B2 JP5778582B2 (ja) | 2015-09-16 |
Family
ID=42233533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011539520A Expired - Fee Related JP5778582B2 (ja) | 2008-12-06 | 2009-12-07 | 有機化合物 |
Country Status (23)
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006133261A2 (en) | 2005-06-06 | 2006-12-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
| AU2007256633B2 (en) | 2006-06-06 | 2013-09-12 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2008063505A1 (en) * | 2006-11-13 | 2008-05-29 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2008070095A1 (en) | 2006-12-05 | 2008-06-12 | Intra-Cellular Therapies, Inc. | Novel uses |
| EP2939676A1 (en) * | 2007-12-06 | 2015-11-04 | Intra-Cellular Therapies, Inc. | Organic compounds |
| ES2588238T3 (es) * | 2007-12-06 | 2016-10-31 | Intra-Cellular Therapies, Inc. | Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico |
| AU2009322899A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| AU2009322903A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| PE20110922A1 (es) * | 2008-12-06 | 2012-01-22 | Intra Cellular Therapies Inc | DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1) |
| BRPI0922700A2 (pt) | 2008-12-06 | 2015-08-11 | Intracellular Therapies Inc | Compostos orgânicos |
| EA201170769A1 (ru) * | 2008-12-06 | 2012-02-28 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| MX2011005934A (es) | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
| WO2010098839A1 (en) | 2009-02-25 | 2010-09-02 | Intra-Cellular Therapies, Inc. | Pde 1 inhibitors for ophthalmic disorders |
| EP2434895A4 (en) | 2009-05-13 | 2013-08-07 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| US8858911B2 (en) | 2009-10-08 | 2014-10-14 | Intra-Cellular Therapies, Inc. | Phosphodiesterase 1-targeting tracers and methods |
| TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| EP2575817A4 (en) | 2010-05-31 | 2014-01-08 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| US9371327B2 (en) | 2010-05-31 | 2016-06-21 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
| US9763948B2 (en) | 2010-05-31 | 2017-09-19 | Intra-Cellular Therapies, Inc. | PDE1 inhibitory compounds and methods |
| EP2717877B1 (en) * | 2011-06-10 | 2017-11-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| EP2782584B1 (en) | 2011-11-23 | 2021-06-09 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9499562B2 (en) | 2012-06-18 | 2016-11-22 | Dart Neuroscience (Cayman) Ltd. | Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| AR091507A1 (es) | 2012-06-21 | 2015-02-11 | Intra Cellular Therapies Inc | SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| EP2956141A4 (en) | 2013-02-17 | 2016-10-26 | Intra Cellular Therapies Inc | NEW USES |
| DK2970279T3 (da) | 2013-03-15 | 2020-11-30 | Intra Cellular Therapies Inc | Organiske forbindelser |
| ES2717688T3 (es) | 2013-03-15 | 2019-06-24 | Intra Cellular Therapies Inc | Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP |
| EP3010509B1 (en) | 2013-06-21 | 2021-07-28 | Intra-Cellular Therapies, Inc. | Free base crystals |
| JP6696904B2 (ja) | 2014-01-08 | 2020-05-20 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 製剤および医薬組成物 |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| DK3157926T3 (da) | 2014-06-20 | 2019-08-19 | Intra Cellular Therapies Inc | Organiske forbindelser |
| KR20170040209A (ko) | 2014-07-29 | 2017-04-12 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 경피 크림 |
| US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
| US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10131671B2 (en) | 2014-08-07 | 2018-11-20 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CA2961212C (en) | 2014-09-17 | 2024-02-06 | Intra-Cellular Therapies, Inc. | Compounds and methods |
| WO2016090382A1 (en) | 2014-12-06 | 2016-06-09 | Intra-Cellular Therapies, Inc. | Organic compounds |
| BR112017012007B1 (pt) | 2014-12-06 | 2022-11-01 | Intra-Cellular Therapies, Inc | Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2 |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| US11291666B2 (en) | 2016-09-12 | 2022-04-05 | Intra-Cellular Therapies, Inc. | Uses |
| JP7401442B2 (ja) | 2018-01-31 | 2023-12-19 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
| JP7493460B2 (ja) | 2018-05-25 | 2024-05-31 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| EP3856191A4 (en) | 2018-09-25 | 2022-06-22 | Intra-Cellular Therapies, Inc. | NOVEL USES |
| US11628171B2 (en) | 2019-03-13 | 2023-04-18 | Children's Medical Center Corporation | Method for treating brain or nerve injury |
| US20220184240A1 (en) | 2019-04-12 | 2022-06-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US12410175B2 (en) | 2019-09-03 | 2025-09-09 | Intra-Cellular Therapies, Inc. | Compounds |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| US12435093B2 (en) | 2020-05-06 | 2025-10-07 | Intra-Cellular Therapies, Inc. | Free base crystals |
| US12364695B2 (en) | 2020-06-02 | 2025-07-22 | Intra-Cellular Therapies, Inc. | Methods of treating inflammatory disease |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666908A (en) | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
| NZ238609A (en) | 1990-06-21 | 1993-12-23 | Schering Corp | Polycyclic guanine derivatives; preparation, pharmaceutical compositions, |
| US5202328A (en) | 1991-03-06 | 1993-04-13 | Merck & Co., Inc. | Substituted fused pyrimidinones |
| US5294612A (en) | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
| EP0686157A1 (en) | 1993-02-26 | 1995-12-13 | Schering Corporation | 2-benzyl-polycyclic guanine derivatives and process for preparing them |
| GB9315017D0 (en) | 1993-07-20 | 1993-09-01 | Glaxo Lab Sa | Chemical compounds |
| US5824683A (en) | 1995-11-28 | 1998-10-20 | Schering Corporation | 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones |
| SE9701398D0 (sv) | 1997-04-15 | 1997-04-15 | Astra Pharma Prod | Novel compounds |
| IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| US6013621A (en) | 1997-10-17 | 2000-01-11 | The Rockfeller University | Method of treating psychosis and/or hyperactivity |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| US6133273A (en) | 1998-05-08 | 2000-10-17 | American Home Products Corporation | Pyrazolopyrimidine-2,4-dione sulfonamides |
| DE19931206A1 (de) | 1999-07-07 | 2001-01-11 | Stief Christian | Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung |
| PL354675A1 (en) | 1999-09-30 | 2004-02-09 | Neurogen Corporation | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
| TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
| HK1049834A1 (zh) | 1999-10-11 | 2003-05-30 | 辉瑞大药厂 | 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物 |
| IL152925A (en) | 1999-10-21 | 2010-04-15 | Pfizer | Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| CN1436080A (zh) | 2000-04-19 | 2003-08-13 | 利利艾科斯有限公司 | 环gmp－特异性磷酸二酯酶抑制剂治疗帕金森氏病的用途 |
| CA2436911A1 (en) | 2001-03-16 | 2002-09-26 | Pfizer Inc. | Pyrazolo`4,3-d.pyrimidinone compounds as cgmp pde inhibitors |
| WO2002088079A2 (en) * | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| SE0102315D0 (sv) | 2001-06-28 | 2001-06-28 | Astrazeneca Ab | Compounds |
| JP4450365B2 (ja) | 2001-08-28 | 2010-04-14 | シェーリング コーポレイション | 多環式グアニンホスホジエステラーゼｖ阻害剤 |
| EP1575916B1 (en) | 2001-08-31 | 2013-05-22 | The Rockefeller University | Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain |
| CN1585771A (zh) * | 2001-11-09 | 2005-02-23 | 先灵公司 | 多环鸟嘌呤衍生物磷酸二酯酶v抑制剂 |
| IL163575A0 (en) | 2002-02-21 | 2005-12-18 | Univ Rockefeller | Compositions and method for regulation of calcium-dependent signalling in brain |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| EP1613747A1 (en) | 2003-03-31 | 2006-01-11 | Pfizer Products Inc. | Crystal structure of 3 ,5 -cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof |
| JP2006522151A (ja) | 2003-04-01 | 2006-09-28 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 不妊症におけるホスホジエステラーゼ阻害剤 |
| EA200600372A1 (ru) | 2003-09-05 | 2006-08-25 | Ньюроджин Корпорейшн | Конденсированные с гетероарилом пиридины, пиразины и пиримидины в качестве лигандов рецептора кортикотропин-рилизинг-фактора (crf 1) |
| WO2006133261A2 (en) | 2005-06-06 | 2006-12-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP1919287A4 (en) | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY |
| AU2007256633B2 (en) | 2006-06-06 | 2013-09-12 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US20070286890A1 (en) * | 2006-06-07 | 2007-12-13 | John Garnett Walt | Eyelash applicator and method |
| WO2008063505A1 (en) * | 2006-11-13 | 2008-05-29 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2008070095A1 (en) | 2006-12-05 | 2008-06-12 | Intra-Cellular Therapies, Inc. | Novel uses |
| EP2939676A1 (en) | 2007-12-06 | 2015-11-04 | Intra-Cellular Therapies, Inc. | Organic compounds |
| ES2588238T3 (es) | 2007-12-06 | 2016-10-31 | Intra-Cellular Therapies, Inc. | Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico |
| BRPI0922700A2 (pt) | 2008-12-06 | 2015-08-11 | Intracellular Therapies Inc | Compostos orgânicos |
| EA201170769A1 (ru) | 2008-12-06 | 2012-02-28 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| PE20110922A1 (es) * | 2008-12-06 | 2012-01-22 | Intra Cellular Therapies Inc | DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1) |
| AU2009322903A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| MX2011005934A (es) | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
| AU2009322899A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2010098839A1 (en) | 2009-02-25 | 2010-09-02 | Intra-Cellular Therapies, Inc. | Pde 1 inhibitors for ophthalmic disorders |
| EP2434895A4 (en) | 2009-05-13 | 2013-08-07 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| US8858911B2 (en) | 2009-10-08 | 2014-10-14 | Intra-Cellular Therapies, Inc. | Phosphodiesterase 1-targeting tracers and methods |
| EP2575817A4 (en) | 2010-05-31 | 2014-01-08 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| US9763948B2 (en) | 2010-05-31 | 2017-09-19 | Intra-Cellular Therapies, Inc. | PDE1 inhibitory compounds and methods |
| TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| US9371327B2 (en) | 2010-05-31 | 2016-06-21 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
| EP2717877B1 (en) * | 2011-06-10 | 2017-11-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
-
2009
- 2009-12-07 PE PE2011001169A patent/PE20110922A1/es not_active Application Discontinuation
- 2009-12-07 MA MA33969A patent/MA32938B1/fr unknown
- 2009-12-07 AU AU2009322901A patent/AU2009322901A1/en not_active Abandoned
- 2009-12-07 CA CA2740391A patent/CA2740391A1/en not_active Abandoned
- 2009-12-07 KR KR1020117013115A patent/KR20110095881A/ko not_active Withdrawn
- 2009-12-07 EP EP09830744.0A patent/EP2367429B1/en active Active
- 2009-12-07 CN CN2009801480893A patent/CN102231953A/zh active Pending
- 2009-12-07 SG SG2011036589A patent/SG171775A1/en unknown
- 2009-12-07 WO PCT/US2009/006439 patent/WO2010065149A1/en not_active Ceased
- 2009-12-07 ES ES09830744.0T patent/ES2638912T3/es active Active
- 2009-12-07 JP JP2011539520A patent/JP5778582B2/ja not_active Expired - Fee Related
- 2009-12-07 US US13/133,033 patent/US8536159B2/en active Active
- 2009-12-07 BR BRPI0922348-7A patent/BRPI0922348A2/pt not_active IP Right Cessation
- 2009-12-07 EA EA201170770A patent/EA201170770A1/ru unknown
- 2009-12-07 MX MX2011005933A patent/MX2011005933A/es not_active Application Discontinuation
-
2011
- 2011-05-17 ZA ZA2011/03631A patent/ZA201103631B/en unknown
- 2011-05-17 TN TN2011000246A patent/TN2011000246A1/fr unknown
- 2011-05-30 CL CL2011001263A patent/CL2011001263A1/es unknown
- 2011-06-02 IL IL213314A patent/IL213314A0/en unknown
- 2011-06-06 DO DO2011000173A patent/DOP2011000173A/es unknown
- 2011-06-06 CR CR20110312A patent/CR20110312A/es unknown
- 2011-06-29 CO CO11081343A patent/CO6390083A2/es active IP Right Grant
- 2011-07-05 EC EC2011011184A patent/ECSP11011184A/es unknown
-
2013
- 2013-09-06 US US14/020,016 patent/US20140005155A1/en not_active Abandoned
-
2014
- 2014-10-03 US US14/506,394 patent/US20150038474A1/en not_active Abandoned
-
2015
- 2015-04-30 US US14/700,746 patent/US20160083390A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011522789A5 (cg-RX-API-DMAC10.html) | ||
| JP2012510523A5 (cg-RX-API-DMAC10.html) | ||
| KR890002045A (ko) | 치환 피리딘술폰아미드 화합물 및 이들을 함유하는 제초 조성물 | |
| JP2007512359A5 (cg-RX-API-DMAC10.html) | ||
| JP2007528417A5 (cg-RX-API-DMAC10.html) | ||
| JP2013510178A5 (cg-RX-API-DMAC10.html) | ||
| JP2015523383A5 (cg-RX-API-DMAC10.html) | ||
| MX2008001395A (es) | Inhibidores macrociclicos del virus de la hepatitis c. | |
| DK1919874T3 (da) | Fremgangsmåde til fremstilling af benzazepinforbindelser eller salte deraf | |
| JP2009515872A5 (cg-RX-API-DMAC10.html) | ||
| WO2010053583A3 (en) | Small molecule cd4 mimetics and uses thereof | |
| JP2016500653A5 (cg-RX-API-DMAC10.html) | ||
| EP0125919A3 (en) | Catechol derivatives, their production and intermediates therefor, and pharmaceutical compositions containing them | |
| JP2017531663A5 (cg-RX-API-DMAC10.html) | ||
| DK1701722T3 (da) | N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidin-2-methansulfonsyresalt | |
| EP1310490A4 (en) | GPR14 ANTAGONIST | |
| AU562246B2 (en) | Hetero substituted phenyl formamidines | |
| WO2005117590A3 (en) | Novel compounds, pharmaceutical compositions containing same, and methods of use for same | |
| JP2007536240A5 (cg-RX-API-DMAC10.html) | ||
| JP2009508971A5 (cg-RX-API-DMAC10.html) | ||
| NO20063111L (no) | Fremgangsmate for fremstilling av tiazolpyrimidiner | |
| PL143732B1 (en) | Method of obtaining amidine derivatives of 2-substituted 4-phenylamidazolone | |
| JP2007517048A5 (cg-RX-API-DMAC10.html) | ||
| JP2020518563A5 (cg-RX-API-DMAC10.html) |